IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$75.81 USD
-1.80 (-2.32%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $75.85 +0.04 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Income Statements
Fiscal Year end for IntraCellular Therapies Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 464 | 250 | 84 | 23 | 0 |
Cost Of Goods | 34 | 20 | 8 | 2 | 0 |
Gross Profit | 431 | 230 | 76 | 21 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 590 | 494 | 361 | 252 | 154 |
Income After Depreciation & Amortization | -159 | -264 | -286 | -231 | -154 |
Non-Operating Income | 20 | 7 | 2 | 4 | 6 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -139 | -256 | -284 | -227 | -148 |
Income Taxes | 1 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -140 | -256 | -284 | -227 | -148 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -140 | -256 | -284 | -227 | -148 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -167 | -263 | -289 | -231 | -155 |
Depreciation & Amortization (Cash Flow) | -8 | 1 | -4 | 0 | -1 |
Income After Depreciation & Amortization | -159 | -264 | -286 | -231 | -154 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 95.88 | 94.05 | 81.25 | 70.37 | 55.19 |
Diluted EPS Before Non-Recurring Items | -1.46 | -2.72 | -3.50 | -3.23 | -2.68 |
Diluted Net EPS (GAAP) | -1.46 | -2.72 | -3.50 | -3.23 | -2.68 |
Fiscal Year end for IntraCellular Therapies Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 161.39 | 144.87 | 132.10 | 126.17 | 110.79 |
Cost Of Goods | 11.35 | 9.90 | 10.70 | 9.13 | 7.16 |
Gross Profit | 150.03 | 134.97 | 121.40 | 117.04 | 103.63 |
SG&A, R&D, and Dept/Amort Expenses | 177.75 | 155.92 | 155.49 | 146.76 | 150.80 |
Income After SG&A, R&D, and Dept/Amort Expenses | -27.72 | -20.95 | -34.09 | -29.72 | -47.17 |
Non-Operating Income | 11.56 | 6.06 | 5.97 | 5.50 | 4.53 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -16.16 | -14.89 | -28.13 | -24.22 | -42.65 |
Income Taxes | 0.06 | 0.36 | 0.45 | 0.04 | 0.14 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -16.22 | -15.25 | -28.58 | -24.26 | -42.78 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -16.22 | -15.25 | -28.58 | -24.26 | -42.78 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 103.72 | 96.88 | 96.29 | 96.14 | 95.95 |
Diluted EPS Before Non-Recurring Items | -0.16 | -0.16 | -0.30 | -0.25 | -0.45 |
Diluted Net EPS (GAAP) | -0.16 | -0.16 | -0.30 | -0.25 | -0.45 |